Novo Nordisk's pricing strategies during the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who's got accused the company of value gouging, declaring the stark distinction amongst U.S. rates and people in Europe and copyright. In October 2024, Novo Nordisk reveal